Annual Review of Economics,
Год журнала:
2022,
Номер
14(1), С. 253 - 285
Опубликована: Апрель 28, 2022
The
COVID-19
pandemic
has
upended
health
and
living
standards
around
the
world.
This
article
provides
an
interim
overview
of
these
effects,
with
a
particular
focus
on
low-
middle-income
countries
(LMICs).
Economists
have
explained
how
is
likely
to
different
consequences
for
LMICs
demands
distinct
policy
responses
compared
those
rich
countries.
We
survey
rapidly
expanding
body
empirical
research
that
documents
pandemic's
many
adverse
economic
noneconomic
effects
in
terms
standards,
education,
health,
gender
equality,
which
appear
be
unprecedented
scope
scale.
also
review
successful
failed
responses,
including
failure
ensure
widespread
vaccine
coverage
LMICs,
needed
end
pandemic.
close
discussion
implications
public
institutions
international
governance,
given
likelihood
future
pandemics
other
major
shocks
(e.g.,
climate).
Vaccines,
Год журнала:
2021,
Номер
9(8), С. 900 - 900
Опубликована: Авг. 13, 2021
Vaccine
hesitancy
forms
a
critical
barrier
to
the
uptake
of
COVID-19
vaccine
in
high-income
countries
or
regions.
This
review
aims
summarize
rates
and
its
determinants
A
scoping
was
conducted
Medline
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Июль 1, 2022
The
COVID-19
pandemic
continues
to
impact
daily
life,
including
health
system
operations,
despite
the
availability
of
vaccines
that
are
effective
in
greatly
reducing
risks
death
and
severe
disease.
Misperceptions
vaccine
safety,
efficacy,
risks,
mistrust
institutions
responsible
for
vaccination
campaigns
have
been
reported
as
factors
contributing
hesitancy.
This
study
investigated
hesitancy
globally
June
2021.
Nationally
representative
samples
1,000
individuals
from
23
countries
were
surveyed.
Data
analyzed
descriptively,
weighted
multivariable
logistic
regressions
used
explore
associations
with
Here,
we
show
more
than
three-fourths
(75.2%)
23,000
respondents
report
acceptance,
up
71.5%
one
year
earlier.
Across
all
countries,
is
associated
a
lack
trust
safety
science,
skepticism
about
its
efficacy.
Vaccine
hesitant
also
highly
resistant
required
proof
vaccination;
31.7%,
20%,
15%,
14.8%
approve
requiring
it
access
international
travel,
indoor
activities,
employment,
public
schools,
respectively.
For
ongoing
succeed
improving
coverage
going
forward,
substantial
challenges
remain
be
overcome.
These
include
increasing
among
those
reporting
lower
confidence
addition
expanding
low-
middle-income
countries.
Persuading
people
to
mask
Even
in
places
where
it
is
obligatory,
tend
optimistically
overstate
their
compliance
for
wearing.
How
then
can
we
persuade
more
of
the
population
at
large
act
greater
good?
Abaluck
et
al
.
undertook
a
large,
cluster-randomized
trial
Bangladesh
involving
hundreds
thousands
(although
mostly
men)
over
2-month
period.
Colored
masks
various
construction
were
handed
out
free
charge,
accompanied
by
range
mask-wearing
promotional
activities
inspired
marketing
research.
Using
grassroots
network
volunteers
help
conduct
study
and
gather
data,
authors
discovered
that
wearing
averaged
13.3%
villages
no
interventions
took
place
but
increased
42.3%
in-person
introduced.
Villages
reinforcement
occurred
also
showed
reduction
reporting
COVID-like
illness,
particularly
high-risk
individuals.
—CA
Journal of Multidisciplinary Healthcare,
Год журнала:
2022,
Номер
Volume 15, С. 21 - 45
Опубликована: Янв. 1, 2022
Abstract:
The
delay
or
refusal
of
vaccination,
which
defines
vaccine
hesitancy,
is
a
major
challenge
to
successful
control
COVID-19
epidemic.
huge
number
publications
addressing
hesitancy
necessitates
periodic
review
provide
concise
summary
acceptance
rates
worldwide.
In
the
current
narrative
review,
data
on
were
retrieved
from
surveys
in
114
countries/territories.
East
and
Southern
Africa
(n
=
9),
highest
rate
was
reported
Ethiopia
(92%),
while
lowest
Zimbabwe
(50%).
West/Central
13),
Niger
(93%),
Cameroon
(15%).
Asia
Pacific
16),
Nepal
Vietnam
(97%),
Hong
Kong
(42%).
Eastern
Europe/Central
7),
Montenegro
(69%)
Kazakhstan
(64%),
Russia
(30%).
Latin
America
Caribbean
20),
Mexico
(88%),
Haiti
(43%).
Middle
East/North
(MENA,
n
22),
Tunisia
Iraq
(13%).
Western/Central
Europe
North
27),
Canada
(91%)
Norway
(89%),
Cyprus
Portugal
(35%).
≥
60%
seen
72/114
countries/territories,
compared
42
countries/territories
with
between
13%
59%.
phenomenon
appeared
more
pronounced
MENA,
Central
Asia,
Africa.
More
studies
are
recommended
Africa,
address
intentions
general
public
get
vaccination.
Keywords:
SARS-CoV-2,
hesitance,
resistance,
rejection,
willingness
vaccinate,
intention
vaccinate
The Lancet Global Health,
Год журнала:
2022,
Номер
10(6), С. e798 - e806
Опубликована: Апрель 23, 2022
Several
countries
have
authorised
or
begun
using
a
booster
vaccine
dose
against
COVID-19.
Policy
makers
urgently
need
evidence
of
the
effectiveness
additional
doses
and
its
clinical
spectrum
for
individuals
with
complete
primary
immunisation
schedules,
particularly
in
where
schedule
used
inactivated
SARS-CoV-2
vaccines.Using
individual-level
data,
we
evaluated
prospective,
observational,
national-level
cohort
(aged
≥16
years)
affiliated
Fondo
Nacional
de
Salud
insurance
programme
Chile,
to
assess
CoronaVac
(Sinovac
Biotech),
AZD1222
(Oxford-AstraZeneca),
BNT162b2
(Pfizer-BioNTech)
boosters
who
had
completed
CoronaVac,
compared
unvaccinated
individuals.
Individuals
administered
vaccines
from
Feb
2,
2021,
prespecified
study
end
date
Nov
10,
were
evaluated;
excluded
probable
confirmed
infection
(RT-PCR
antigen
test)
on
before
received
at
least
one
any
COVID-19
2021.
We
estimated
laboratory-confirmed
symptomatic
(symptomatic
COVID-19)
cases
outcomes
(hospitalisation,
admission
intensive
care
unit
[ICU],
death
inverse
probability-weighted
stratified
survival
regression
models
estimate
hazard
ratios,
accounting
time-varying
vaccination
status
adjusting
relevant
demographic,
socioeconomic,
confounders.
change
vaccinated
associated
series
vaccine.11
174
257
eligible
this
study,
among
whom
4
127
546
(two
doses)
during
period.
1
921
340
(46·5%)
participants
an
booster,
2
019
260
(48·9%)
186
946
(4·5%)
homologous
CoronaVac.
calculated
adjusted
(weighted
Cox
model)
preventing
78·8%
(95%
CI
76·8-80·6)
three-dose
96·5%
(96·2-96·7)
93·2%
(92·9-93·6)
booster.
The
COVID-19-related
hospitalisation,
ICU
admission,
was
86·3%
(83·7-88·5),
92·2%
(88·7-94·6),
86·7%
(80·5-91·0)
96·1%
(95·3-96·9),
96·2%
(94·6-97·3),
96·8%
(93·9-98·3)
97·7%
(97·3-98·0),
98·9%
(98·5-99·2),
98·1%
(97·3-98·6)
booster.Our
results
suggest
that
heterologous
provides
high
level
protection
COVID-19,
including
severe
disease
death.
Heterologous
showed
higher
than
all
outcomes,
providing
support
mix-and-match
approach.Agencia
Investigación
y
Desarrollo
through
Científico
Tecnológico,
Millennium
Science
Initiative
Program,
Financiamiento
Centros
en
Áreas
Prioritarias.
Vaccines,
Год журнала:
2021,
Номер
9(11), С. 1243 - 1243
Опубликована: Окт. 25, 2021
The
current
crisis
created
by
the
coronavirus
pandemic
is
impacting
all
facets
of
life.
Coronavirus
vaccines
have
been
developed
to
prevent
infection
and
fight
pandemic.
Since
might
be
only
way
stop
spread
coronavirus.
World
Health
Organization
(WHO)
has
already
approved
several
vaccines,
many
countries
started
vaccinating
people.
Misperceptions
about
persist
despite
evidence
vaccine
safety
efficacy.To
explore
scientific
literature
find
determinants
for
worldwide
COVID-19
hesitancy
as
reported
in
literature.PRISMA
Extension
Scoping
Reviews
(PRISMA-ScR)
guidelines
were
followed
conduct
a
scoping
review
on
willingness
vaccinate.
Several
databases
(e.g.,
MEDLINE,
EMBASE,
Google
Scholar)
searched
relevant
articles.
Intervention-
(i.e.,
vaccine)
outcome-
hesitancy)
related
terms
used
search
these
databases.
was
conducted
22
February
2021.
Both
forward
backward
reference
lists
checked
further
studies.
Three
reviewers
worked
independently
select
articles
extract
data
from
selected
literature.
Studies
that
quantitative
survey
measure
acceptance
included
this
review.
extracted
synthesized
following
narrative
approach
results
represented
graphically
with
appropriate
figures
tables.82
studies
882
identified
our
search.
Sometimes,
had
performed
same
country,
it
observed
high
earlier
decreased
over
time
hope
efficacy.
People
different
varying
percentages
uptake
(28-86.1%),
(10-57.8%),
refusal
(0-24%).
most
common
affecting
vaccination
intention
include
efficacy,
side
effects,
mistrust
healthcare,
religious
beliefs,
trust
information
sources.
Additionally,
intentions
are
influenced
demographic
factors
such
age,
gender,
education,
region.The
underlying
complex
context-specific,
across
socio-demographic
variables.
Vaccine
can
also
other
health
inequalities,
socioeconomic
disadvantages,
systemic
racism,
level
exposure
misinformation
online,
some
being
more
dominant
certain
than
others.
Therefore,
strategies
tailored
cultures
socio-psychological
need
reduce
aid
informed
decision-making.